source
- Argenx shares tumble 15% after Phase 3 Sjögren’s study of Vyvgart halted for futilityArgenx reported that an independent monitoring board recommended stopping its Phase 3 trial of Vyvgart in Sjögren’s disease due to futility, based on an interim analysis. The decision came earlier…
- Par Health recalls two lots of Brevital Sodium injection over cellulose particlesPar Health announced a voluntary recall of two lots of its Brevital® Sodium 500 mg/vial for injection after detecting particulate matter identified as cellulose. The recall is being executed at th…